EuroEyes International Eye Clinic Limited
德視佳國際眼科有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1846)

PROFIT ALERT

This announcement is made by EuroEyes International Eye Clinic Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**", each a "**Director**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Interim Period**") and other information currently available to the Board, the Group expects to record a loss attributable to owners of the Company in the range of HK$10 million to HK$17 million for the Interim Period, as compared to a profit attributable to owners of the Company of approximately HK$38.4 million for the corresponding period in 2025.

The Board considers that the expected turnaround from profit to loss as compared to the corresponding period in 2025, was primarily attributable to (a) non-recurring costs directly associated with the acquisition of FYEO Europe B.V., which was completed on 22 July 2026, comprising principally advisory and professional fees incurred in connection with the transaction; and (b) the operating losses incurred by the Group's Switzerland operations, following the completion of the Switzerland acquisition on 13 October 2025, and amidst an ongoing strategic turnaround.

As the acquisition of FYEO Europe B.V. was completed on 22 July 2026, subsequent to the end of the Interim Period, the revenues and results of FYEO Europe B.V. are not included in the Group's consolidated financial results for the Interim Period. The financial contribution of FYEO Europe B.V. will be reflected in the Group's consolidated financial results with effect from the second half of the financial year ending 31 December 2026.

Notwithstanding the expected loss, the Board remains confident that the core business and underlying operations of the Group remain stable. During the Interim Period, the Group's revenue is expected to be in the range of approximately HK$450 million to HK$460 million, representing an increase in the range of approximately 19% to 22%, as compared to approximately HK$377.1 million for the corresponding period in 2025. This growth reflects the continued expansion of the Group's core business, the inclusion of the Switzerland segment for the first time, and the Group's sound operating performance across its principal markets.

Excluding one-off acquisition-related costs and the operating losses attributable to the Switzerland turnaround, the Group's normalised net profit attributable to owners of the Company for the Interim Period is expected to be broadly in line with the corresponding period in 2025.

The Company is still in the process of finalising the consolidated financial results for the Interim Period. The information contained in this announcement is only a preliminary assessment by the Board based on the information currently available and the unaudited consolidated management accounts of the Group for the Interim Period, which have not been audited or reviewed by the Company's independent auditor and/or the audit committee of the Board. The actual results of the Group for the Interim Period may be different from what is disclosed in this announcement.

Shareholders and potential investors are advised to read carefully the announcement of the interim results of the Group for the Interim Period, which is expected to be published by the end of August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Dr. Jørn Slot Jørgensen
Chairman and Executive Director

Hong Kong, 24 August 2026

As at the date of this announcement, the Board comprises Dr. Jørn Slot Jørgensen, Mr. Jannik Jonas Slot Jørgensen, Professor Dan Zoltan Reinstein, Mr. Marcus Huascar Bracklo and Mr. Rens Laurentius Michaël Schoenmakers as executive Directors; and Mr. Hans Helmuth Hennig, Ms. Katherine Rong Xin and Mr. Philip Duncan Wright as independent non-executive Directors.